Skip to main content

Heliogen, Inc. Announces Second Quarter 2023 Financial and Operational Results

Heliogen, Inc. (“Heliogen”) (NYSE: HLGN), a leading provider of AI-enabled concentrating solar energy technology, today provided its second quarter 2023 financial and operational results.

Recent Highlights

  • Increased current opportunity pipeline to 825 MW, 700 MW of which was added since May 2023

Second Quarter 2023 Highlights

  • Signed an $11.2 million offtake contract with the City of Lancaster, CA for the sale of carbon-free green hydrogen produced at Heliogen’s Proxima project

Executive Commentary

“During the second quarter of 2023, we made demonstrable progress on our three-pronged strategy to enhance shareholder value at Heliogen,” said Christie Obiaya, Heliogen’s Chief Executive Officer. “We advanced our goal of closing sales by securing a high-quality green hydrogen offtake agreement.”

Ms. Obiaya continued, “Heliogen’s efforts remain focused on expanding our market presence, accelerating the installation of our first commercial-scale projects, and preparing to add growth capital. We have seen rapid progress on these strategic initiatives, which is a testament to our team’s resilience and dedication. As we look forward to the next several quarters, we remain focused and determined to unlock the vast potential of our groundbreaking solar thermal energy technology. We stand resolute in our commitment to deliver on the promises we’ve made to our shareholders, customers and the planet.”

Second Quarter 2023 Financial Results

For the second quarter 2023, Heliogen reported total revenue of $1.4 million and net loss of $21.7 million. Heliogen’s revenue was driven primarily by continued execution on its Capella project. Heliogen’s Adjusted EBITDA was negative $19.3 million for second quarter 2023.

Conference Call Information

The Heliogen management team will host a conference call to discuss its second quarter 2023 financial results on Wednesday, August 9, 2023, at 10:00 a.m. EDT. The call can be accessed via a live webcast accessible on the Events & Presentations page in the Investor Relations section of Heliogen’s website at www.heliogen.com. The call can also be accessed live via telephone by dialing 1-877-407-0789 (1-201-689-8562 for international callers) and referencing Heliogen.

An archive of the webcast will also be available shortly after the call on the Investor Relations section of Heliogen’s website.

Open Conference Call Question Submission

Members of the investor community may submit questions before the start of the conference call for consideration via email to louis.baltimore@heliogen.com.

About Heliogen

Heliogen is a renewable energy technology company focused on decarbonizing industry and empowering a sustainable civilization. The company’s concentrating solar energy and thermal storage systems aim to deliver carbon-free heat, steam, power, or green hydrogen at scale to support round-the-clock industrial operations. Powered by AI, computer vision and robotics, Heliogen is focused on providing robust clean energy solutions that accelerate the transition to renewable energy, without compromising reliability, availability, or cost. For more information about Heliogen, please visit heliogen.com.

Use of Non-GAAP Financial Information

Management uses certain financial measures, including EBITDA and Adjusted EBITDA, to evaluate our financial and operating performance that are calculated and presented on the basis of methodologies other than in accordance with generally accepted accounting principles in the United States of America (��GAAP”). We believe these non-GAAP financial measures are useful to investors and analysts to assess our ongoing financial performance because they provide improved comparability between periods through the exclusion of certain items that we believe are not indicative of our core operating performance, enhance the overall understanding of our past financial performance and future prospects, and remove items that may obscure our underlying business results and trends. These measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP, and our calculations thereof may not be comparable to similarly titled measures reported by other companies.

EBITDA represents consolidated net loss before (i) interest (income) expense, net, (ii) income tax expense (benefit) and (iii) depreciation and amortization expense. We define Adjusted EBITDA as EBITDA adjusted for certain significant non-cash items and items that management believes are not attributable to or indicative of our on-going operations or that may obscure our underlying results and trends. Please see the accompanying tables for a reconciliation of net loss to EBITDA and Adjusted EBITDA.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements that are not historical in nature, including the words “anticipate,” “expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “will,” “forecast” and other similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding our commitment to accelerating our sales and establishing stronger relationships with our commercial partners, expanding our market presence and accelerating the installation of our first commercial-scale project, achieving our financial and operational goals and future growth opportunities. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our financial and business performance, including risk of uncertainty in our financial projections and business metrics and any underlying assumptions thereunder; (ii) changes in our business and strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; (iii) our ability to execute our business model, including market acceptance of our planned products and services and achieving sufficient production volumes at acceptable quality levels and prices; (iv) our ability to maintain listing on the New York Stock Exchange; (v) our ability to access sources of capital to finance operations, growth and future capital requirements; (vi) our ability to maintain and enhance our products and brand, and to attract and retain customers; (vii) our ability to scale in a cost effective manner; (viii) changes in applicable laws or regulations; (ix) developments and projections relating to our competitors and industry; and (x) our ability to protect our intellectual property. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the “Risk Factors” section in Part I, Item 1A in our Annual Report on Form 10-K for the annual period ended December 31, 2022, as supplemented in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 and other documents filed by Heliogen from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Heliogen assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

 

Heliogen, Inc.

Condensed Consolidated Statements of Operations

($ in thousands, except per share and share data)

(unaudited)

 

 

Three Months Ended

 

Six Months Ended

 

June 30,

 

June 30,

 

2023

 

2022

 

2023

 

2022

Revenue

$

1,394

 

 

$

2,392

 

 

$

3,331

 

 

$

5,931

 

Cost of revenue

 

1,522

 

 

 

2,814

 

 

 

3,904

 

 

 

40,638

 

Gross loss

 

(128

)

 

 

(422

)

 

 

(573

)

 

 

(34,707

)

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

Selling, general and administrative

 

17,652

 

 

 

22,403

 

 

 

21,817

 

 

 

42,465

 

Research and development

 

4,946

 

 

 

5,905

 

 

 

10,206

 

 

 

15,280

 

Impairment charges

 

 

 

 

 

 

 

1,008

 

 

 

 

Total operating expenses

 

22,598

 

 

 

28,308

 

 

 

33,031

 

 

 

57,745

 

Operating loss

 

(22,726

)

 

 

(28,730

)

 

 

(33,604

)

 

 

(92,452

)

 

 

 

 

 

 

 

 

Interest income, net

 

270

 

 

 

213

 

 

 

553

 

 

 

407

 

Gain (loss) on warrant remeasurement

 

(52

)

 

 

8,284

 

 

 

252

 

 

 

12,310

 

Other income (expense), net

 

827

 

 

 

(109

)

 

 

574

 

 

 

(185

)

Net loss before taxes

 

(21,681

)

 

 

(20,342

)

 

 

(32,225

)

 

 

(79,920

)

(Provision) benefit for income taxes

 

(2

)

 

 

125

 

 

 

(2

)

 

 

735

 

Net loss

$

(21,683

)

 

$

(20,217

)

 

$

(32,227

)

 

$

(79,185

)

 

 

 

 

 

 

 

 

Loss per share:

 

 

 

 

 

 

 

Loss per share – Basic and Diluted

$

(0.11

)

 

$

(0.11

)

 

$

(0.16

)

 

$

(0.42

)

Weighted average number of shares outstanding – Basic and Diluted

 

200,616,841

 

 

 

190,182,474

 

 

 

198,768,335

 

 

 

187,123,737

 

 

Heliogen, Inc.

Condensed Consolidated Balance Sheets

($ in thousands)

(unaudited)

 

 

June 30, 2023

 

December 31, 2022

ASSETS

 

 

 

Cash and cash equivalents

$

43,498

 

$

45,719

Investments, available-for-sale

 

64,309

 

 

97,504

Other current assets

 

14,642

 

 

15,598

Total current assets

 

122,449

 

 

158,821

Non-current assets

 

31,469

 

 

32,798

Total assets

$

153,918

 

$

191,619

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

 

Trade payables

$

845

 

$

6,921

Contract liabilities

 

12,247

 

 

10,348

Contract loss provisions

 

27,500

 

 

28,418

Other current liabilities

 

9,784

 

 

5,602

Total current liabilities

 

50,376

 

 

51,289

Long-term liabilities

 

15,222

 

 

15,006

Total liabilities

 

65,598

 

 

66,295

Shareholders’ equity

 

88,320

 

 

125,324

Total liabilities and shareholders’ equity

$

153,918

 

$

191,619

 

Heliogen, Inc.

Reconciliation of Net Loss to EBITDA and Adjusted EBITDA

($ in thousands)

(unaudited)

 

 

Three Months Ended

 

Six Months Ended

 

June 30,

 

June 30,

 

2023

 

2022

 

2023

2022

Net loss

$

(21,683

)

 

$

(20,217

)

 

$

(32,227

)

 

$

(79,185

)

Interest income, net

 

(270

)

 

 

(213

)

 

 

(553

)

 

 

(407

)

Provision (benefit) for income taxes

 

2

 

 

 

(125

)

 

 

2

 

 

 

(735

)

Depreciation and amortization

 

592

 

 

 

540

 

 

 

1,193

 

 

 

1,178

 

EBITDA

$

(21,359

)

 

$

(20,015

)

 

$

(31,585

)

 

$

(79,149

)

Impairment charges (1)

 

 

 

 

 

 

 

1,008

 

 

 

 

Gain on warrant remeasurement (2)

 

52

 

 

 

(8,284

)

 

 

(252

)

 

 

(12,310

)

Share-based compensation (3)

 

2,816

 

 

 

11,524

 

 

 

(6,490

)

 

 

24,506

 

Provision for contract losses (4)

 

20

 

 

 

 

 

 

390

 

 

 

33,737

 

Contract losses incurred (4)

 

(877

)

 

 

(3,189

)

 

 

(1,324

)

 

 

(3,160

)

Change in fair value of contingent consideration (5)

 

112

 

 

 

39

 

 

 

1,237

 

 

 

53

 

Employee retention credit (6)

 

(41

)

 

 

 

 

 

(41

)

 

 

 

Adjusted EBITDA

$

(19,277

)

 

$

(19,925

)

 

$

(37,057

)

 

$

(36,323

)

_______________

(1)

Represents the impairment of goodwill associated with the acquisition of HelioHeat GmbH (the “HelioHeat Acquisition”).

(2)

Represents the change in fair value on our outstanding warrant liabilities.

(3)

Share-based compensation for the six months ended June 30, 2023 includes a net reduction of $12.5 million of expense as a result of stock options forfeited in connection with the termination of our former Chief Executive Officer and excludes $0.1 million of expense associated with the vesting of warrants issued in April 2022 in connection with a vendor agreement (the “Vendor Warrants”). Share-based compensation for the three and six months ended June 30, 2022 excludes $0.1 million of expense associated with the vesting of the Vendor Warrants.

(4)

Represents contract losses with customers for which estimated costs to satisfy performance obligations exceeded considerations expected to be realized. Contract loss is reduced and recognized in cost of revenue as expenditures are incurred and related revenue is recognized.

(5)

Represents the change in fair value of our contingent consideration related to the HelioHeat Acquisition.

(6)

Represents an adjustment to the employee tax credit to the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) recorded as grant revenue in the fourth quarter of 2022.

 

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.